ECSP077739A - Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar - Google Patents

Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar

Info

Publication number
ECSP077739A
ECSP077739A EC2007007739A ECSP077739A ECSP077739A EC SP077739 A ECSP077739 A EC SP077739A EC 2007007739 A EC2007007739 A EC 2007007739A EC SP077739 A ECSP077739 A EC SP077739A EC SP077739 A ECSP077739 A EC SP077739A
Authority
EC
Ecuador
Prior art keywords
ezetimibe
cholesterol
sch
treatment
inhibitors
Prior art date
Application number
EC2007007739A
Other languages
English (en)
Inventor
Poblete Juan Francisco Miquel
Oddone Flavio Nervi
Rivera Atilio Gianpietro Gigotti
Matsuhiro Silvana Zanlungo
Original Assignee
Univ Pontificia Catolica Chile
Mimica Timosenko Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40329103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pontificia Catolica Chile, Mimica Timosenko Ivan filed Critical Univ Pontificia Catolica Chile
Publication of ECSP077739A publication Critical patent/ECSP077739A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención demuestra que el uso de inhibidores específicos de la absorción intestinal de colesterol del tipo 2-AZETIDINONAS, específicamente EZETIMIBE (SCH 58235), inhibe completamente la formación de colelitiasis en un modelo murino de la enfermedad bajo dieta litogénica. Esta invención en un modelo preclínico de la enfermedad litiásica por cálculos de colesterol permite predecir que el bloqueo selectivo de la absorción intestinal de colesterol constituye una alternativa terapéutica eficaz en la prevención primaria y/o en el tratamiento de la colelitiasis en humanos. A su vez, como se argumentó en la sección del arte previo, es posible predecir que en humanos la combinación de ezetimibe (SCH 58235) más inhibidores de la neosíntesis hepática de colesterol (inhibidores de HMG-CoA reductasa), pudieran ser más eficaces que ezetimibe (SCH 58235) sólo para prevenir y/o tratar la litiasis vesicular.
EC2007007739A 2005-04-04 2007-09-14 Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar ECSP077739A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2005000762 2005-04-04

Publications (1)

Publication Number Publication Date
ECSP077739A true ECSP077739A (es) 2008-01-23

Family

ID=40329103

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007739A ECSP077739A (es) 2005-04-04 2007-09-14 Uso de ezetimibe para la prevención y tratamiento de cálculos de colesterol en la vía biliar

Country Status (6)

Country Link
US (1) US8361999B2 (es)
EP (1) EP1865947A1 (es)
BR (1) BRPI0609614A2 (es)
EC (1) ECSP077739A (es)
MX (1) MX2007012253A (es)
WO (1) WO2006107936A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2875975A1 (en) * 2012-06-06 2013-12-12 Unither Virology, Llc Novel iminosugars and their applications
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN110327449A (zh) * 2019-07-15 2019-10-15 王天罡 一种治疗胆结石的中药组合物及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
CN1678296A (zh) * 2002-07-30 2005-10-05 卡里凯昂公司 依泽替米贝的组合物和治疗胆固醇有关的良性与恶性肿瘤的方法
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
HRP20070241T3 (hr) * 2003-12-19 2007-07-31 Bristol-Myers Squibb Company Azabiciklički heterocikli kao modulatori kanabinoid receptora

Also Published As

Publication number Publication date
US8361999B2 (en) 2013-01-29
US20100016273A1 (en) 2010-01-21
WO2006107936A1 (en) 2006-10-12
EP1865947A1 (en) 2007-12-19
BRPI0609614A2 (pt) 2010-04-20
MX2007012253A (es) 2007-12-07

Similar Documents

Publication Publication Date Title
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
EP2063852A4 (en) AQUEOUS CLEANSING, DISINFECTANT AND / OR STERILIZING AGENT WITH LOW PEROXYAN COMPONENT
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
EP1856236A4 (en) AQUEOUS DISINFECTANTS AND STERILIZERS
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
WO2007126841A3 (en) Inhibition of alpha-synuclein toxicity
PA8759601A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
UY29633A1 (es) Derivados de oxindol
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
CR10165A (es) "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"
ECSP088117A (es) Agente desinfectante
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
BRPI0607562A2 (pt) derivados da diosmetina para o tratamento e a prevenção das patologias trombóticas
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
NO20063368L (no) Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
CL2007003561A1 (es) Uso de una composicion que contiene uno o mas agentes anticonvulsion aguda y es bioadherente a la mucosa oral y/o nasal humana para tratar convulsion aguda, convulsiones repetitivas y estado epileptico.
EP1961494A4 (en) WASTE TREATMENT STRUCTURE OF A SPRAYER
PL1683418T3 (pl) Kompozycje do higienicznej dezynfekcji rąk i do dezynfekującego mycia rąk
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.